Deep Blue Medical Advances announced the closing of an oversubscribed $5.6 million Series A financing round alongside the promotion of Lou Fuqua to chief operating officer.
The funding will support the commercial launch of the company’s biosynthetic absorbable T-Line Mesh, expansion into aesthetic and breast surgery applications, and continued collaboration with hospital systems and key opinion leaders.
Deep Blue is focused on improving outcomes in soft tissue surgery by addressing suture pull-through, a leading cause of surgical failure. Its platform includes T-Line Mesh, suture systems, and aesthetic scaffolds designed to enhance tissue reinforcement and defect closure.
The company’s technology is supported by a growing body of clinical evidence, including 18 peer-reviewed publications, 21 issued patents, and more than 20,000 implanted procedures over five years, demonstrating safety and efficacy across multiple use cases.
In conjunction with the financing, Lou Fuqua has been promoted from senior vice president to chief operating officer. Fuqua brings experience scaling medical device companies and will oversee quality, regulatory affairs, product development, and manufacturing as the company enters its next phase of growth.
The announcement reflects increasing demand for innovative surgical solutions and positions Deep Blue to expand commercialization efforts and broaden its product applications in the healthcare market.
KEY QUOTES
“This oversubscribed round reflects strong investor confidence in our platform and the clinical evidence behind it. With 18 peer-reviewed publications, 21 issued patents, and more than 20,000 patented lockstitches and extensions implanted over five years — including multi-center long-term follow-up demonstrating high efficacy and excellent safety — Deep Blue is exceptionally well-positioned to scale. The pipeline is full, the evidence is strong, and the timing is right.”
Bill Perry, Chief Executive Officer, Deep Blue Medical Advances
“Suture pull-through and surgical failure represent a significant, underappreciated problem — and we have a compelling solution. I’m proud of what this team has built and excited about what comes next.”
Lou Fuqua, Chief Operating Officer, Deep Blue Medical Advances
